Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

T1D Exchange

- PMLiVE

Eli Lilly to sell low blood sugar drug Baqsimi to Amphastar in deal worth over $1bn

The drug is available in 27 markets, with worldwide sales totalling over $139m in 2022

- PMLiVE

Tiziana to develop intranasal foralumab for type 1 diabetes

Approximately 4.7 million people in the UK are currently living with diabetes

- PMLiVE

Novo Nordisk and Aspect Biosystems partner in billion dollar deal for diabetes treatments

The deal to develop a new class of disease-modifying treatments could be worth up to $2.6bn

- PMLiVE

Novo Nordisk and Dewpoint partner on insulin resistance drug candidates

Insulin resistance affects around 15.5% to 46.5% of the world’s population

- PMLiVE

Sanofi to cut US insulin prices by up to 78% in January 2024

The announcement follows similar moves by Novo Nordisk and Eli Lilly earlier this month

- PMLiVE

Novo Nordisk to cut US insulin prices by up to 75% in January 2024

The decision comes just weeks after Eli Lilly announced a similar series of price cuts

- PMLiVE

Sanofi to acquire Provention Bio in deal worth $2.9bn

The merger includes recently-approved type 1 diabetes prevention therapy Tzield

- PMLiVE

Medscape Education Wins Best Practice Award for Learner Outcomes at NAMEC

This year's winners have been announced  for the National Association of Medical Education Companies (NAMEC) awards. These awards recognize best practices-ideas or processes that can be implemented by NAMEC members to...

Medscape Education Global

- PMLiVE

Tidepool’s automated insulin dosing app for type 1 diabetes gets FDA approval

Tidepool Loop is the first app of its kind to receive clearance in the US

- PMLiVE

Eli Lilly announces $450m investment in US manufacturing site

In December 2022 increased demand resulted in a short supply of two of its diabetes drugs

- PMLiVE

Eli Lilly and EVA Pharma collaborate to enhance insulin access in Africa

The African-made insulin products are expected to reach one million people per year by 2030

- PMLiVE

FDA approves first drug to delay onset of type 1 diabetes

Provention Bio’s Tzield delayed the average onset of type 1 diabetes by over four years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links